Christiane Pott

A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling

Michael Hummel, Stefan Bentink, Hilmar Berger et al. · New England Journal of Medicine · 2006 · 1K citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

Alessandro Pastore, Vindi Jurinović, Robert Kridel et al. · The Lancet Oncology · 2015 · 613 citations

Medicine, Immunology, Oncology +17

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia

Monika Brüggemann, Thorsten Raff, Thomas Flohr et al. · Blood · 2005 · 537 citations

Medicine, Hematology, Oncology +16

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)

Roswitha Forstpointner, Michael Unterhalt, Martin Dreyling et al. · Blood · 2006 · 465 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma

Constantine S. Tam, Mary Ann Anderson, Christiane Pott et al. · New England Journal of Medicine · 2018 · 429 citations

Medicine, Pharmacology, Pharmacotherapy +13